Dermatologic uses of omalizumabFootnote^*

^*The article has been presented by Dr. Chia as a poster at the 2015 American Academy of Dermatology Annual Meeting (San Francisco, California).

References

• Ames SA, Gleeson CD, Kirkpatrick P. Omalizumab. Nat Rev Drug Discov. 2004;3:199–200.
   PubMed Web of Science ®Google Scholar
• Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530–7.
   PubMed Web of Science ®Google Scholar
• London VA, Kim GH, Fairley JA, Woodley DT. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012;148:1241–3.
   PubMedGoogle Scholar
• Bard S, Paravisini A, Aviles-Izquierdo JA, et al. Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol. 2008;144:1662–3.
   PubMed Web of Science ®Google Scholar
• Sokol KC, Ghazi A, Kelly BC, Grant JA. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract. 2014;2:266–70.
   PubMed Web of Science ®Google Scholar
• Babu KS, Polosa R, Morjaria JB. Anti-IgE-emerging opportunities for omalizumab. Expert Opin Biol Ther. 2013;13:765–77.
   PubMed Web of Science ®Google Scholar
• Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:157–62.
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67–75.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Canada Inc. Xolar (omalizumab) product monograph, 2015. p. 1–53. Available from https://www.novartis.ca/sites/www.novartis.ca/files/xolair_scrip_e.pdf.
   Google Scholar
• Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137:1742–50.
   PubMed Web of Science ®Google Scholar
• Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134:560–7. e4.
   PubMed Web of Science ®Google Scholar
• Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2:525–36. e1.
   PubMed Web of Science ®Google Scholar
• Centre for Evidence-Based Medicine. Available from http://www.cebm.net/. Accessed May 26, 2016.
   Google Scholar
• Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39:777–87.
   PubMed Web of Science ®Google Scholar
• Metz M, Staubach P, Bauer A, et al. Omalizumab normalizes levels of high affinity immunoglobulin E receptor-positive skin cells in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study. J Invest Dermatol. 2014;134:S30–S8.
   Web of Science ®Google Scholar
• Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128:202–9.
   PubMed Web of Science ®Google Scholar
• Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567–73.
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101–9.
   PubMed Web of Science ®Google Scholar
• Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1-antihistamine resistant chronic spontaneous urticaria patients: results from X-ACT, a randomised controlled trial. Allergy. 2016;71:1135–44.
   Google Scholar
• Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150:288–90.
   PubMed Web of Science ®Google Scholar
• Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154:177–80.
   PubMed Web of Science ®Google Scholar
• Aubin F, Avenel-Audran M, Jeanmougin M, et al. Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study. J Am Acad Dermatol. 2016;74:574–5.
   PubMed Web of Science ®Google Scholar
• Muller S, Schempp CM, Jakob T. Failure of omalizumab in the treatment of solar urticaria. J Eur Acad Dermatol Venereol. 2016;30:524–5.
   PubMed Web of Science ®Google Scholar
• Duchini G, Baumler W, Bircher AJ, Scherer K. Failure of omalizumab (Xolair(R)) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed. 2011;27:336–7.
   PubMed Web of Science ®Google Scholar
• Vieira Dos Santos R, Locks Bidese B, Rabello de Souza J, Maurer M. Effects of omalizumab in a patient with three types of chronic urticaria. Br J Dermatol. 2014;170:469–71.
   PubMed Web of Science ®Google Scholar
• Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:247–9.
   PubMed Web of Science ®Google Scholar
• Le Moing A, Becourt C, Pape E, et al. Effective treatment of idiopathic chronic cold urticaria with omalizumab: report of 3 cases. J Am Acad Dermatol. 2013;69:e99–101.
   PubMed Web of Science ®Google Scholar
• Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy. 2010;65:138–9.
   PubMed Web of Science ®Google Scholar
• Bullerkotte U, Wieczorek D, Kapp A, Wedi B. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy. 2010;65:931–2.
   PubMed Web of Science ®Google Scholar
• Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117:1415–8.
   PubMed Web of Science ®Google Scholar
• Zimmer S, Peveling-Oberhag A, Weber A, et al. Unique coexistence of cold and solar urticaria and its efficient treatment. Br J Dermatol. 2016;174:1150–2.
   PubMed Web of Science ®Google Scholar
• Brodska P, Schmid-Grendelmeier P. Treatment of severe cold contact urticaria with omalizumab: case reports. Case Rep Dermatol. 2012;4:275–80.
   PubMedGoogle Scholar
• Iyengar SR, Hoyte EG, Loza A, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162:89–93.
   PubMed Web of Science ®Google Scholar
• Hotze M, Baurecht H, Rodriguez E, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy. 2014;69:132–5.
   PubMed Web of Science ®Google Scholar
• Dimson OG, Giudice GJ, Fu CL, et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol. 2003;120:784–8.
   PubMed Web of Science ®Google Scholar
• Yu KK, Crew AB, Messingham KA, et al. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71:468–74.
   PubMed Web of Science ®Google Scholar
• Dufour C, Souillet AL, Chaneliere C, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol. 2012;166:1140–2.
   PubMed Web of Science ®Google Scholar
• Ohameje NU, Loveless JW, Saini SS. Atopic dermatitis or hyper-IgE syndrome? Allergy Asthma Proc. 2006;27:289–91.
   PubMed Web of Science ®Google Scholar
• Chularojanamontri L, Wimoolchart S, Tuchinda P, et al. Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pac J Allergy Immunol. 2009;27:233–6.
   PubMed Web of Science ®Google Scholar
• Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55:168–70.
   PubMed Web of Science ®Google Scholar
• Lieberoth S, Thomsen SF. Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab. Case Rep Med. 2015;2015:903541. doi: 10.1155/2015/903541.
   PubMed Web of Science ®Google Scholar
• Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126:1099–104e4.
   PubMed Web of Science ®Google Scholar
• Siebenhaar F, Kuhn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. J Allergy Clin Immunol. 2007;120:213–15.
   PubMed Web of Science ®Google Scholar
• Yalcin AD. A case of Netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels. Immunopharmacol Immunotoxicol. 2016;38:162–6.
   PubMed Web of Science ®Google Scholar
• Ghazanfar MN, Thomsen SF. Omalizumab for urticarial vasculitis: case report and review of the literature. Case Rep Dermatol Med. 2015;2015:576893. doi: 10.1155/2015/576893.
   PubMedGoogle Scholar
• Uzun R, Yalcin AD, Celik B, et al. Levofloxacin induced toxic epidermal necrolysis: successful therapy with omalizumab (anti-IgE) and pulse prednisolone. Am J Case Rep. 2016;17:666–71.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Madioni C, Olivieri C, et al. Churg-Strauss vasculitis in a patient treated with omalizumab. J Asthma. 2008;45:115–16.
   PubMed Web of Science ®Google Scholar
• Wechsler M, Wong D, Miller M, Lawrence-Miyasaki L. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009;136:507–18.
   PubMed Web of Science ®Google Scholar
• Jachiet M, Samson M, Cottin V, et al. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheum. 2016;68:2274–82.
   PubMed Web of Science ®Google Scholar